AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Medicus Pharma Ltd. Common Stock
Video analysis: MDCX
All videosNo video analysis for this stock yet. Request one from our team.
News: MDCX
Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress across its SkinJect program and a co-development and licensing opportunity with Pfizer, with CEO Raza Bokhari highlighting clinical, partnership and funding developments as the company sharpens its focus on precision oncology and capital-efficient drug development. Bokhari said final SkinJect results published on ClinicalTrials.gov had confirmed the 200-microgram patch as the dose to be taken forward into further registrational studies.
Wall Street sets positive tone as investors digest hotter inflation data
Positive tone Wall Street opened sharply higher on Friday, with the Dow Jones Industrial Average and S&P 500 both gaining 1.1% and the Nasdaq rising 1.2% as...
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment
Medicus Pharma (NASDAQ:MDCX) said a completed Phase 2 study of its SkinJect therapy showed all 90 enrolled patients finished treatment without discontinuations, data the company says will guide its next-stage registrational trial in a rare genetic skin cancer syndrome. The randomized, double-blind, multicenter trial enrolled patients across 10 US investigative sites, comparing two dose levels of SkinJect against a device-only microneedle comparator.
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
CSR provides a clinical foundation for the Company's recently announced capital-efficient focus on FDA-authorized Gorlin Syndrome NDA-enabling development program while supporting partnership discussions to advance nodular Basal Cell Carcinoma CSR provides a clinical foundation for the Company's recently announced capital-efficient focus on FDA-authorized Gorlin Syndrome NDA-enabling development program while supporting partnership discussions to advance nodular Basal Cell Carcinoma
Dow falls as Treasury yields jump to highest level since 2023
10:05am: Rising yields pressure stocks Stocks moved lower at the open on Thursday as Treasury yields climbed to their highest level in years and oil prices...
Wall Street slips for a third straight day as oil and yields climb
4:20pm: Treasury yields climb Wall Street extended its selloff on Wednesday, with the Dow Jones Industrial Average falling 440 points as oil prices topped...
Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs
Medicus Pharma (NASDAQ:MDCX) is repositioning itself as a precision oncology-led biotechnology company, centering its strategy on CD228V, a second-generation antibody-drug conjugate targeting CD228-expressing solid tumors, the company said Tuesday. CD228V is now the company's principal strategic priority, with initial development focused on establishing clinical proof-of-concept in a selected tumor population.
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect® and Teverelix® indications Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect® and Teverelix® indications
Similar companies
-
Telomir Pharmaceuticals, Inc. Common Stock
TELO
·
NASDAQ
Compare
-
CEL-SCI Corporation
CVM
·
New York Stock Exchange Arca
Compare
-
Barinthus Biotherapeutics plc
BRNS
·
NASDAQ
Compare
-
Karyopharm Therapeutics Inc.
KPTI
·
NASDAQ
Compare
-
Century Therapeutics, Inc.
IPSC
·
NASDAQ
Compare
-
INmune Bio, Inc.
INMB
·
NASDAQ
Compare